The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
1 88 Re DD-3B6/22 Fab' for use in therapy of ovarian cancer: labelling and animal studies - Pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10
A fast and high yielding method of 188 Re radiolabelling DD-3B6/22 Fab' is described. An inert atmosphere [N 2 (g)] and ascorbic acid was essential for preparation and storage of therapeutic levels (=<2 GBq/mg) for up to 24 h. Immunoreactivity was greater than 75%. Pharmacokinetic studies in nu/nu mice demonstrated localisation of 188 Re DD-3B6/22 Fab' was equivalent and correlated well with the behaviour observed for 99m Tc DD-3B6/22 Fab' used to image ovarian cancer. Excellent stability at the target site in vivo supports the potential use of 188 Re DD-3B6/22 Fab' in the therapy of ovarian cancer.
Radiopharmaceutical Division Research and Development, Australian Nuclear Science and Technology Organisation (ANSTO), private mail bag no.1, Menai, NSW, Australia
Radiopharmaceutical Division Research and Development, Australian Nuclear Science and Technology Organisation (ANSTO), private mail bag no.1, Menai, NSW, Australia